Across the globe, countries are being challenged by the SARS-CoV-2 (COVID-19)
pandemic in ways they have never been before. The global outbreak of SARS-CoV-2 with …

Severe acute respiratory syndrome (SARS) is an emerging infectious disease caused by a
novel human coronavirus (CoV). During the 2003 epidemic, the disease rapidly spread from …

A series of 2-(benzylthio)-6-oxo-4-phenyl-1, 6-dihydropyrimidine as SARS-CoV 3CL
protease inhibitors were developed and their potency was evaluated by in vitro protease …

Inhibition of coronavirus (CoV)‐encoded papain‐like cysteine proteases (PLpro) represents
an attractive strategy to treat infections by these important human pathogens. Herein we …

SARS coronavirus main proteases (3CL proteases) have been validated as
pharmacological targets for the treatment of coronavirus infections. Current inhibitors of …

Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) identified in 2003
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …

Coronaviruses, which were discovered in 1968, can lead to some human viral disorders, like
severe acute respiratory syndrome (SARS), Middle East respiratory syndrome-related …

Two viral proteases of severe acute respiratory syndrome coronavirus (SARS-CoV), a
chymotrypsin-like protease (3CLpro) and a papain-like protease (PLpro) are attractive …

Abstract The Severe Acute Respiratory Syndrome (SARS) is a serious life-threatening and
strikingly mortal respiratory illness caused by SARS-CoV. SARS-CoV which contains a …

The SARS‐CoV‐2 coronavirus encodes an essential papain‐like protease domain as part of
its non‐structural protein (nsp)‐3, namely SARS2 PLpro, that cleaves the viral polyprotein …